Abstract:Nanomedicine involves the use of engineered nanoscale materials in an extensive range of diagnostic and therapeutic applications and can be applied to the treatment of many diseases. Despite the rapid progress and tremendous potential of nanomedicine in the past decades, the clinical translational process is still quite slow, owing to the difficulty in understanding, evaluating, and predicting nanomaterial behaviors within the complex environment of human beings. Microfluidics-based organ-on-a-chip (Organ Chip) techniques offer a promising way to resolve these challenges. Sophisticatedly designed Organ Chip enable in vitro simulation of the in vivo microenvironments, thus providing robust platforms for evaluating nanomedicine. Herein, we review recent developments and achievements in Organ Chip models for nanomedicine evaluations, categorized into seven broad sections based on the target organ systems: respiratory, digestive, lymphatic, excretory, nervous, and vascular, as well as coverage on applications relating to cancer. We conclude by providing our perspectives on the challenges and potential future directions for applications of Organ Chip in nanomedicine.

What problem does this paper attempt to address?

The main problem this paper attempts to address is the challenges in the clinical translation of nanomedicine, particularly how to better understand and evaluate the behavior of nanomaterials in the complex human environment. Specifically, the paper focuses on using organ-on-a-chip platforms based on microfluidic technology to accelerate the evaluation of nanomedicine. ### Background and Issues 1. **Development of Nanomedicine**: - Nanomedicine shows great potential in diagnosing and treating various diseases, but its clinical translation process remains slow. - The main reason is the lack of sufficient understanding of the circulation, interaction, and toxicity of nanomaterials in the human body. 2. **Limitations of Traditional Evaluation Methods**: - **Animal Models**: Although animal models help track the transport of nanomedicine in vivo, differences in physiological responses between animals and humans may lead to misunderstandings of its efficacy and toxicity. - **2D Cell Culture Models**: Traditional 2D cell culture models cannot accurately simulate the growth environment and function of cells in vivo, thus failing to effectively predict the in vivo toxicity and other biological effects of nanomedicine. 3. **Improvements in 3D Cell Culture Models**: - 3D cell culture models can better simulate cell-cell or cell-matrix interactions in vivo but still have limitations under static culture conditions, such as changes in nanoparticle sedimentation and transport kinetics. ### Solution 1. **Organ-on-a-chip Technology**: - Organ-on-a-chip is a 3D cell culture platform based on microfluidic technology that can simulate the complex dynamic microenvironment in vivo. - These chips provide a culture environment closer to real physiological conditions by precisely controlling nutrient exchange, oxygen supply, and physiological shear stress. 2. **Advantages of Organ-on-a-chip**: - **Accurate Evaluation of Nanomedicine Transport and Trans-tissue Interface Transport**: Under physiologically relevant shear flow conditions, organ-on-a-chip can more accurately evaluate the behavior of nanomedicine. - **Real-time Exploration of Nanomedicine Biological Mechanisms**: By monitoring subtle changes in different parts of the organ/tissue, it reveals the targeting effects and adverse reactions of nanomedicine. - **Reduction of Animal Experiments**: Organ-on-a-chip can provide more accurate and reliable preclinical data, reducing reliance on animal experiments. ### Application Areas 1. **Respiratory System**: - Using lung-on-a-chip to study the transport of nanoparticles across the alveolar-capillary barrier and the inflammatory response they cause. 2. **Digestive System**: - Using liver-on-a-chip and intestine-on-a-chip to simulate the interaction of nanoparticles through gastrointestinal and liver tissues, assessing the liver damage they cause. 3. **Lymphatic System**: - Using spleen-on-a-chip to study the application of magnetic nanoparticles in clearing pathogens from the blood of sepsis patients. 4. **Excretory System**: - Using kidney-on-a-chip to monitor the damage of nanoparticles in the kidneys. 5. **Nervous System**: - Using blood-brain barrier-on-a-chip to evaluate the efficiency of nanoparticles penetrating the blood-brain barrier. 6. **Vascular System**: - Using vascular-on-a-chip and vascular-tumor-on-a-chip to verify the extravasation, targeting specificity, and accumulation of nanoparticles. 7. **Tumor/Cancer**: - Using tumor/cancer-on-a-chip to evaluate the targeting, transport, and accumulation efficiency of nanoparticles. ### Conclusion This paper summarizes the latest advances in the evaluation of nanomedicine using organ-on-a-chip and proposes future research directions and challenges. Through these advanced technologies, it is expected to accelerate the clinical translation of nanomedicine, improving its safety and efficacy.

Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine